Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
October 23, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored...
Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital
October 04, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored...
Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine
October 02, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored...
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger
September 13, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif. and CHARLOTTESVILLE, Va., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company, and Lewis and Clark Pharmaceuticals...
Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
September 12, 2017 09:49 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of...
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals to Merge
May 30, 2017 16:15 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif. and CHARLOTTESVILLE, Va., May 30, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company, and Lewis and Clark Pharmaceuticals, a...
Inspyr Therapeutics Signs Commitment Letter with Milost Global
March 28, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of...
Inspyr Therapeutics Secures a $100 Million Financing Agreement from Milost Global
March 17, 2017 09:00 ET
|
Inspyr Therapeutics
Commitment of up to $100 Million in Total Proceeds Transaction Subject to Definitive Agreement WESTLAKE VILLAGE, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a...
Inspyr Therapeutics Appoints NIH Veterans to Lead New Translational Medicine Initiatives and Pipeline Expansion
March 06, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of...
Inspyr Therapeutics Initiates Mipsagargin Combination Therapy Program for Gastric Cancer
February 22, 2017 09:00 ET
|
Inspyr Therapeutics
WESTLAKE VILLAGE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company developing novel therapeutics for the treatment of cancer, today...